Patient characteristics.

<p>List of abbreviations: AIDS, acquired immunodeficiency syndrome; HAART, highly-active antiretroviral treatment; HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibodies; HIV, human immunodeficiency virus; INR, immunological non-responders; IQR, interquartile range; IR, Immunological responders; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</p><p>Patient characteristics.</p

Severe non AIDS-related events observed during the follow-up (overall results and stratified by immunological response at year 1).

<p>List of abbreviations: AIDS, acquired immunodeficiency syndrome; eGFR, estimated glomerular filtration rate; INR, immunological non-responders; IR, Immunological responders.</p><p>Severe non AIDS-related events observed during the follow-up (overall results and stratified by immunological response at year 1).</p

Proportion of patients remaining free from severe non AIDS-related event.

<p>List of abbreviations: AIDS, acquired immunodeficiency syndrome; HAART, Highly-active antiretroviral therapy.</p

Multivariable Cox Proportional Hazard Models for Time to first AIDS-defining event or severe non AIDS-defining event or death.

<p>List of abbreviations: AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HAART, highly-active antiretroviral treatment; HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibodies; HIV, human immunodeficiency virus; INR, immunological non-responders; IR, Immunological responders; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</p><p>¹ The first model was adjusted for age and gender.</p><p>² The second model was adjusted for age, gender, intravenous drug use as route of HIV transmission, pre-HAART CD4+ T-cell count, occurrence of AIDS-defining events and immunological response (Immunological non responders at year 1 <i>versus</i> responders). Occurrence of AIDS-defining event during follow-up was considered as time-dependent variable</p><p>* Estimates for HCV-Ab positivity were not adjusted for intravenous drug use as route of HIV transmission, due to high correlation.</p><p>Multivariable Cox Proportional Hazard Models for Time to first AIDS-defining event or severe non AIDS-defining event or death.</p

Multivariable Cox Proportional Hazard Models for Time to severe non-AIDS related event.

<p>List of abbreviations: AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HAART, highly-active antiretroviral treatment; HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibodies; HIV, human immunodeficiency virus; INR, immunological non-responders; IR, Immunological responders; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.</p><p>¹ The first model was adjusted for age and gender.</p><p>² The second model was adjusted for age, gender, intravenous drug use as route of HIV transmission, pre-HAART CD4+ T-cell count, occurrence of AIDS-defining events and immunological response (Immunological non responders at year 1 <i>versus</i> responders). Occurrence of AIDS-defining event during follow-up was considered as time-dependent variable.</p><p>* Estimates for HCV-Ab positivity were not adjusted for intravenous drug use as route of HIV transmission, due to high correlation.</p><p>Multivariable Cox Proportional Hazard Models for Time to severe non-AIDS related event.</p

Additional file 1: Table S1. of The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort

Multivariable logistic regression model: association of demographical and clinical features with advanced HIV disease according to observation period. Table S2. Survival rate at year-1 and at year-5 from 1985 to 2009 according to late presentation and advanced HIV disease (weighted for losses to follow-up). (DOCX 23 kb

Mean eGFR annual change (ml/min) among patients developing mild renal impairment during treatment with tenofovir.

<p>Results from the GEE multivariate linear model.</p

Characteristics of patients developing mild renal impairment under TDF.

<p>Characteristics of patients developing mild renal impairment under TDF.</p

Association between current TDF use and CKD, based on cumulative exposure to TDF after mild renal impairment occurrence.

<p>eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0162320#pone.0162320.ref008" target="_blank">8</a>] Chronic Kidney Disease was defined as two eGFR <60 ml/min measured 3–6 months apart. Abbreviations: CI, confidence interval; CKD, chronic kidney disease; TDF, tenofovir disoproxil fumarate.</p

Flow chart illustrating the entire study population.

<p>Flow chart illustrating the entire study population.</p